NEVOLATINJECTION

Novo Nordisk redirected manufacturing capacity toward newer, higher-demand medicines such as Wegovy — a portfolio decision, not a safety issue. Liraglutide remains fully licensed, and the generic (Nevolat) is widely available in the UK.

Clinically, yes: the same active ingredient, doses, licence conditions and pen format, made by Zentiva. Generics must prove equivalence to the brand — the differences are the name and, usually, the price.

Trial average: ~8% of body weight over 56 weeks at the full dose with lifestyle support — a third of participants lost over 10%. The licence's own checkpoint applies: 5%+ by 12 weeks on the full dose, or treatment is reconsidered.

If you're progressing and tolerating it well — no need. If you've plateaued or want more, the evidence favours the weekly options (roughly double and triple liraglutide's average loss respectively). Switching requires a prescriber-managed plan; raise it at your next review or in a fresh consultation.

Duration of action: liraglutide lasts about 24 hours; semaglutide and tirzepatide are engineered to last a week. Not a strength ranking in itself — and the fast clearance cuts both ways, offering quicker reversibility if you stop or react.

Residual branded stock has essentially gone from the UK supply chain and no more is being made. Nevolat is the standard fulfilment; if your prescription names Saxenda, we can arrange the equivalent supply.

It has the longest safety record in the class — over a decade in weight management and longer in diabetes — with three-year continuous-use trial data and a stable, well-characterised profile. Known cautions (thyroid history, pancreatitis, heart rate) are screened in consultation.

Twelve weeks after reaching the full 3 mg dose, we review your weight against your baseline. At 5%+ loss, treatment continues with routine monitoring; below that, we'll recommend stopping or switching — the evidence says pushing on rarely pays, and a weekly option is usually the better move.